Medscape
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious than standard therapy alone, according to a new phase 3, placebo-controlled study. In the trial, 46.4% of patients in the obinutuzumab group had a complete renal response at 76 weeks compared with 33.1% of those in the standard therapy …
Read More
Obinutuzumab a Success in Phase 3 Trial for Lupus Nephritis
Diego Ramage
07:20
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious than standard therapy alone, according to a new phase 3, placebo-controlled study. In the trial, 46.4% of patients in the obinutuzumab group had a complete renal response at 76 weeks compared with 33.1% of those in the standard therapy
